EIA
AXSM icon

Emerald Investment Advisers’s Axsome Therapeutics AXSM Stock Holding History

Emerald Investment Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.01M Buy
28,630
+1,244
+5% +$270K 0.47% 65
2026
Q1 		$4.63M Buy
+27,386
New +$4.73M 0.42% 83

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Emerald Investment Advisers's AXSM Position: Q2 2026 in Review

Emerald Investment Advisers increased its Axsome Therapeutics (AXSM) stake by 4.5% in Q2 2026, buying an estimated $270K and bringing the position to 28,630 shares worth $7.01M. The position accounts for 0.47% of the portfolio, ranked #65.

Emerald Investment Advisers first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Emerald Investment Advisers held 28,630 shares of Axsome Therapeutics worth $7.01M as of Q2 2026.
  • Emerald Investment Advisers bought 1,244 Axsome Therapeutics shares in Q2 2026, an estimated $270K.
  • Axsome Therapeutics made up 0.47% of Emerald Investment Advisers's portfolio in Q2 2026, its #65 holding.
  • Emerald Investment Advisers first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Emerald Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.